Literature DB >> 11470017

Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes.

N Chapman1, B Neal.   

Abstract

Randomized trials have provided clear evidence of the beneficial effects of many different blood pressure-lowering regimens compared with placebo. The comparative effects of antihypertensive regimens based on different drug classes are less well established. The Blood Pressure Lowering Treatment Trialists' Collaboration conducted a series of prospectively designed overviews of randomized trials that compared the effects of different drug classes on major cause-specific outcomes. These overviews found no differences between the effects of regimens based on angiotensin converting enzyme inhibitors and those based on diuretics or b-blockers. There was limited evidence of small differences between regimens based on calcium antagonists and those based on diuretics or beta-blockers. The overviews of regimens based on calcium antagonists compared with those based on angiotensin converting enzyme inhibitors recorded too few events to provide reliable findings. Over the next few years, the findings of ongoing trials and future cycles of overview analyses conducted by the Collaboration should substantially add to these data.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470017     DOI: 10.1007/s11906-001-0097-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  40 in total

1.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.

Authors:  S MacMahon; N Sharpe; G Gamble; A Clague; C N Mhurchu; T Clark; H Hart; J Scott; H White
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the Nurses' Health Study.

Authors:  K B Michels; B A Rosner; J E Manson; M J Stampfer; A M Walker; W C Willett; C H Hennekens
Journal:  Circulation       Date:  1998-04-28       Impact factor: 29.690

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 5.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.

Authors:  R Collins; S MacMahon
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

6.  Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.

Authors: 
Journal:  J Hypertens       Date:  1998-02       Impact factor: 4.844

7.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

8.  Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration.

Authors: 
Journal:  Lancet       Date:  1995 Dec 23-30       Impact factor: 79.321

9.  Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.

Authors:  L Wilhelmsen; G Berglund; D Elmfeldt; T Fitzsimons; H Holzgreve; J Hosie; P E Hörnkvist; K Pennert; J Tuomilehto; H Wedel
Journal:  J Hypertens       Date:  1987-10       Impact factor: 4.844

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  2 in total

Review 1.  Epidemiology and risk profile of heart failure.

Authors:  Anh L Bui; Tamara B Horwich; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2010-11-09       Impact factor: 32.419

2.  Hypertension in women: latest findings and clinical implications.

Authors:  Helga Gudmundsdottir; Aud Høieggen; Aud Stenehjem; Bård Waldum; Ingrid Os
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.